Gilead seeks FDA nod for new HIV quad
This article was originally published in Scrip
Executive Summary
Gilead Sciences is seeking the FDA's approval to market a once-daily single tablet regimen containing elvitegravir 150mg, cobicistat 150mg, emtricitabine 200mg and tenofovir alafenamide (TAF) 10mg for the treatment of HIV-1 infection in adults.